The capital raise lands in a period of heightened regulatory visibility. On July 20, 2026, the FDA accepted Dyne's biologics license application for zeleciment rostudirsen (z-rostudirsen) in exon 51-amenable Duchenne muscular dystrophy, granted Priority Review, and set a PDUFA target action date of January 21, 2027. The submission is based on dystrophin as a surrogate endpoint under the accelerated approval pathway. Topline data from the registrational cohort of the DELIVER trial, released in December 2025, showed a 5.46% increase at six months in dystrophin protein concentrations, along with improvements in functional measures including time-to-rise velocity and the 10-meter walk/run test.
Analyst commentary has framed the regulatory milestone in competitive terms. Oppenheimer told investors it anticipates a "smooth approval" and that z-rostudirsen is poised to "capture the majority of market share" given stronger dystrophin benefits and a more convenient once-every-four-weeks dosing profile versus Sarepta Therapeutics' weekly Exondys 51. Jefferies described the early data cut as "best-in-class" and noted that z-rostudirsen "could command a pricing premium" if approved, with robust uptake expected across treatment-naïve patients, those who have discontinued Exondys, and those currently receiving it.